SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026

Sarepta Therapeutics NASDAQ: SRPT reported second-quarter 2026 total revenue of $401 million, down 3

Sarepta Therapeutics (NASDAQ: SRPT) reported second-quarter 2026 total revenue of $401 million, down

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.64 per share, beating the Zacks C

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the busin

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a l

Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael ​Severino i

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims

Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sa

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sec

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps lea

U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, hea

U.S. stocks closed higher on Wednesday, with the Dow Jones Industrial Average up 0.66% at 46,429.49,

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh

Natural gas jumps over 30% on winter storm disruptions, silver posts its biggest daily surge since 2

Gold and silver surged to fresh record highs Monday as investors reassessed the Federal Reserve'

'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screeni

Dyne Therapeutics reported positive results from Phase 1/2 DELIVER trial for z-rostudirsen in DMD am

Wall Street kicked off December with stocks slightly easing after a strong late-November rally, as r

All eyes are on Nvidia Corp. (NASDAQ:NVDA) as the world's most valuable company prepares to repo

Retail investors are preparing for another busy week of earnings season with more than 1,600 compani

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys appro

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record